Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
SJ Bagley, S Kothari, C Aggarwal, JM Bauml, EW Alley… - Lung cancer, 2017 - Elsevier
Objectives Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been
limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma …
limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma …
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large …
A Russo, M Russano, T Franchina, MR Migliorino… - Advances in …, 2020 - Springer
Introduction Immune checkpoint inhibitors have provided substantial benefit in non-small
cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the …
cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the …
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
A Nakaya, T Kurata, H Yoshioka, Y Takeyasu… - International journal of …, 2018 - Springer
Background There is an unmet need to identify markers that predict the response to
nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to …
nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to …
Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non–small-cell lung cancer: a prospective observational study
T Fukui, Y Okuma, Y Nakahara, S Otani, S Igawa… - Clinical lung cancer, 2019 - Elsevier
Background The immune checkpoint inhibitor nivolumab is entering routine oncologic
practice. We investigated the safety and efficacy of nivolumab in the real world and …
practice. We investigated the safety and efficacy of nivolumab in the real world and …
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
D Cao, H Xu, X Xu, T Guo, W Ge - Oncoimmunology, 2018 - Taylor & Francis
Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC)
worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC …
worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC …
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with …
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum… - Lung cancer, 2017 - Elsevier
Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
Background The absolute neutrophil count (ANC), absolute lymphocyte count (ALC),
absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known …
absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known …
The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer
T Kiriu, M Yamamoto, T Nagano, D Hazama, R Sekiya… - PloS one, 2018 - journals.plos.org
Background Nivolumab improves the survival of advanced non-small cell lung cancer
(NSCLC), but a significant number of patients still fail to benefit from this treatment. In this …
(NSCLC), but a significant number of patients still fail to benefit from this treatment. In this …
[HTML][HTML] Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
K Sekine, S Kanda, Y Goto, H Horinouchi, Y Fujiwara… - Lung Cancer, 2018 - Elsevier
Objectives Nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal
antibody, has been shown to yield a durable response and significant prolongation of the …
antibody, has been shown to yield a durable response and significant prolongation of the …
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
T Shiroyama, H Suzuki, M Tamiya, A Tamiya… - Cancer …, 2018 - Wiley Online Library
Abstract Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating
nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline …
nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline …
相关搜索
- small cell lung cancer
- cell lung cancer time series
- marker of outcomes lung cancer
- predictive biomarker lung cancer
- nivolumab monotherapy lung cancer
- early marker lung cancer
- surrogate marker lung cancer
- lung cancer inflammation index
- overall survival lymphocyte count
- prognostic markers in patients
- nivolumab in patients pooled analysis
- outcomes in patients lung cancer
- early marker outcomes in patients
- surrogate marker nivolumab monotherapy